![](https://news.europawire.eu/wp-content/uploads/2016/02/Merck-GROUP-LOGO.png)
Subgroup analysis shows >80% reduction in the risk of disability progression with Cladribine Tablets vs placebo DARMSTADT, 02-May-2017 — /EuropaWire/ — Merck, a leading science and technology company, announced the presentation of new analyses of efficacy and safety data for … Read the full press release